The infrastructure established for infectious disease vaccines is now accelerating clinical trials for personalized oncology applications. Custom mRNA sequences designed from patient tumor sequencing are entering late-stage trials.
Clinical Trial Outcomes
Early trial data indicates enhanced T-cell responses against specific neoantigens without severe systemic toxicity. Manufacturing pipelines can now generate patient-specific doses within weeks of biopsy processing.